Skip to Content

Data on PolyMedix Antimicrobial Polymers Presented at AmericanSociety of Microbiology 6th Annual Biodefense and Emerging DiseasesResearch Meeting

RADNOR, Pa.--(BUSINESS WIRE)--Feb 26, 2008 - PolyMedix, Inc. (OTC BB: PYMX), an emerging biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, announced that Dr. Byron Brehm-Stecher presented data yesterday at the "American Society of Microbiology 6th Annual Biodefense and Emerging Diseases Research Meeting" in Baltimore relating to PolyMedix's proprietary antimicrobial compounds.

Dr. Byron Brehm-Stecher of Iowa State University, whose work is supported in part by a grant from PolyMedix, presented a poster presentation relating to the activity of some of PolyMedix's antimicrobial polymer compounds against certain biowarfare pathogens, including S. typhimurium, L. onocytogenes, Y. enterocolitica and E. coli O157:H7, and the enhancement of the activity of the polymers by agents called sesquiterpenoids. The title of the presentation was "Wide-Spectrum Biomimetic Antimicrobial Systems". The sesquiterpenoids are compounds commonly used in many applications, such as food additives. PolyMedix has filed a patent application for the use of sesquiterpenoids to enhance the activity of its polymers.

About PolyMedix

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of serious, life-threatening acute infectious diseases and cardiovascular disorders. PolyMedix's compounds are based on biomimetics: non-peptide small molecule drugs that mimic the activity of proteins. The Company's heptagonist compounds reverse the activity of both heparin and low molecular weight heparins, in keeping with the goal of developing an antagonist drug that is safer and easier to use than currently approved therapy. The Company's antibiotic compounds - small molecule mimetics of human host-defense proteins - are believed to have a completely different mechanism of action from all current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. These compounds are being developed as rapidly acting antibiotics for serious systemic and local infections. The Company is also developing polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. PolyMedix plans to file IND applications during the first quarter of 2008 in anticipation of commencing human clinical trials for both its heptagonist and antibiotic compounds.

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and that could cause PolyMedix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has tried, wherever possible, to identify these forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends" and similar expressions. Among other things, there can be no assurance that PolyMedix's compounds will enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedix's filings with the Securities and Exchange Commission.

Posted: February 2008